**Technology Advisory Committee B Interests Register**

**Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer [ID1605]**

**Publication Date: 07/07/2021**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Name | Role with NICE | Type of interest | Description of interest | Interestarose | Interestdeclared | Interest ceased | Comments |
| Dr Nicolas Latimer | TA Committee B Member | Direct - financial | Received payment by Ferring to provide economic modelling advice on rebyota for clostridium difficile infection, in May 2020. Ferring manufacture a comparator drug. | NA | 10/03/2021 | NA | It was agreed that this declaration did not prevent Dr Latimer from participating in this section of the meeting.  |
| Mr Peter Wheatley Price | TA Committee B Member  | Direct - financial | Employed by Takeda who manufacture a comparator product for enzalutamide. | NA | 14/04/2020 | NA | It was agreed that this declaration would prevent Mr Wheatley Price from participating in this section of the meeting and he was asked to leave for the duration of the item. |
| Mr Peter Wheatley Price | TA Committee B Member  | Direct - financial | Employed by Takeda who manufacture Prostap/Prostap DCS (leuprorelin acetate) which is listed as a comparator drug. | NA | 16/03/2021 | NA | It was agreed that this declaration did not prevent Mr Wheatley-Price from participating in this section of the meeting.  |
| Professor Nicholas James | Clinical Expert  | Indirect interests | Previous institution received funding for clinical trials.  | NA | 15/10/2019 | NA | It was agreed that this declaration would not prevent Professor James from providing expert advice to the committee. |
| Professor Nicholas James | Clinical Expert  | Direct - financial | Consultancy work and lecturing from Sanofi, Janssen, Astellas, Clovis and Bayer.  | NA | 15/10/2019 | NA | It was agreed that this declaration would not prevent Professor James from providing expert advice to the committee. |
| Professor Nicholas James | Clinical Expert  | Non-financial professional and personal interest  | Chief investigator on the STAMPEDE trials. | NA | 15/10/2019 | NA | It was agreed that this declaration would not prevent Professor James from providing expert advice to the committee. |
| Dr Stephen Allen | Patient Expert | Indirect interest | Dr Allen’s employer, Tackle Prostate Cancer received unrestricted funding from Astellas and Janssen. | NA | 23/03/2020 | NA | It was agreed that this declaration would not prevent Dr Allen from providing expert advice to the committee. |
| Ms Jane Hocking | Patient Expert | Indirect interest | Ms Hocking’s employer, Prostate Cancer UK have received funding for specific projects from Bayer and Janssen. | NA | 30/04/2020 | NA | It was agreed that this declaration would not prevent Ms Hocking from providing expert advice to the committee. |